WSTAM
CASI

Wilbanks Smith & Thomas Asset Management’s CASI Pharmaceuticals CASI Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16
Closed -$1K – 491
2018
Q3 		$1K Buy
+16
New +$1.12K ﹤0.01% 1497

Other funds holding CASI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's CASI Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of CASI Pharmaceuticals (CASI) in Q4 2018, closing a stake of 16 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in CASI in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 54 funds tracked by Wall St. Rank hold CASI as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining CASI Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 16 CASI Pharmaceuticals shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in CASI Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's CASI Pharmaceuticals position peaked at $1K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.